{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:50:45Z","timestamp":1761540645432},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.ejim.2005.03.003","type":"journal-article","created":{"date-parts":[[2005,8,5]],"date-time":"2005-08-05T11:14:44Z","timestamp":1123240484000},"page":"257-266","source":"Crossref","is-referenced-by-count":5,"title":["New antithrombotics in the prevention of thromboembolic disease"],"prefix":"10.1016","volume":"16","author":[{"given":"Yshai Y.","family":"Yavin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Wolozinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ejim.2005.03.003_bib1","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0735-1097(03)00478-9","article-title":"Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor\/factor VIIa complex, in patients undergoing elective coronary angioplasty","volume":"41","author":"Moons","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2005.03.003_bib2","first-page":"312","volume":"36","author":"Lincoff","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2005.03.003_bib3","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1073\/pnas.92.13.6152","article-title":"Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa","volume":"92","author":"Capello","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejim.2005.03.003_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2796.2003.01224.x","article-title":"Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa\/tissue factor","volume":"254","author":"Ay","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2005.03.003_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/hc2601.091386","article-title":"Dose\u2013response study of recombinant factor VIIa\/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative VTE in patients undergoing total knee replacement","volume":"104","author":"Lee","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2005.03.003_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement","volume":"344","author":"Turpie","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2005.03.003_bib7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of VTE after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2005.03.003_bib8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of VTE in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2005.03.003_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of VTE after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2005.03.003_bib10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of VTE after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2005.03.003_bib11","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery. A meta-analysis of 4 randomised double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2005.03.003_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1613491","article-title":"Steering Committees of the Pentasaccharide Orthopaedic Prophylaxis Studies. Efficacy of safety of fondaparinux in major orthopaedic surgery according to the timing of its administration","volume":"90","author":"Turpie","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2005.03.003_bib13","first-page":"304","article-title":"Influence of the duration of fondaparinux prophylaxis in preventing VTE following hip fracture surgery [abstract]","volume":"100","author":"Bauer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2005.03.003_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(00)05249-1","article-title":"Extended-duration prophylaxis against VTE after total hip or knee replacement: a meta-analysis of the randomised trials","volume":"358","author":"Eikelboom","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2005.03.003_bib15","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1001\/archinte.162.17.1966","article-title":"Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomised study","volume":"162","author":"Prandoni","year":"2002","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2005.03.003_bib16","first-page":"OC006","article-title":"A randomised double-blind study to compare the efficacy and safety of fondaparinux with alteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS study [abstract]","volume":"1","author":"Agnelli","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2005.03.003_bib17","first-page":"2406","article-title":"Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS) [abstract]","volume":"1","author":"Cohen","year":"2003","journal-title":"J Thromb Haemost Suppl"},{"key":"10.1016\/j.ejim.2005.03.003_bib18","first-page":"301","article-title":"A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation [abstract]","volume":"100","author":"Persist Investigators","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2005.03.003_bib19","first-page":"11","volume":"102","author":"Lassen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2005.03.003_bib20","first-page":"11","article-title":"Effects of BAY 59-7939, an oral, direct factor Xa inhibitor, on thrombin generation in healthy volunteers. [abstract]","volume":"102","author":"Harder","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2005.03.003_bib21","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.0000016351.12759.52","article-title":"First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation","volume":"105","author":"Dyke","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejim.2005.03.003_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1538-7933.2004.00594.x","article-title":"Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI pilot","volume":"2","author":"Alexander","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2005.03.003_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/hq0302.105375","article-title":"A human antibody that inhibits factor IX\/Xa function potently inhibits arterial thrombosis without increasing bleeding","volume":"22","author":"Refino","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2005.03.003_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-0038-1657503","article-title":"The protein C pathway: new insights","volume":"78","author":"Esmon","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2005.03.003_bib25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"issue":"3 suppl.","key":"10.1016\/j.ejim.2005.03.003_bib26","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1378\/chest.124.3_suppl.26S","article-title":"The protein C pathway","volume":"124","author":"Esmon","year":"2003","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2005.03.003_bib27","doi-asserted-by":"crossref","first-page":"OC329","DOI":"10.1111\/j.1538-7836.2003.tb05793.x","article-title":"Phase 1 study of a novel recombinant human soluble thrombomodulin ART-123 [abstract]","volume":"1","author":"Moll","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2005.03.003_bib28","first-page":"OC329","article-title":"A dose response study of a recombinant soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement [abstract]","volume":"1","author":"Kearon","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2005.03.003_bib29","first-page":"558","article-title":"Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement. [abstract]","volume":"100","author":"Hull","year":"2002","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2005.03.003_bib30","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(03)00249-4","article-title":"The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review","volume":"109","author":"Gustafsson","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2005.03.003_bib31","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/01.CIR.90.4.1624","article-title":"Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial","volume":"90","author":"Antman","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2005.03.003_bib32","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post infarction angina. Hirulog Angioplasty Study Investigators","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2005.03.003_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00133080","article-title":"Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study","volume":"3","author":"Herman","year":"1996","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.ejim.2005.03.003_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.ejim.2005.03.003_bib35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0049-3848(98)00192-3","article-title":"Synthetic inhibitors of thrombin and factor Xa: from bench to bedside","volume":"93","author":"Hauptmann","year":"1999","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2005.03.003_bib36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-0037-1612978","article-title":"A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: methro I","volume":"87","author":"Eriksson","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2005.03.003_bib37","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(02)11469-3","article-title":"Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the Methro II randomized trial","volume":"360","author":"Eriksson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2005.03.003_bib38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-0037-1613445","article-title":"Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of VTE after total hip or knee joint replacement","volume":"89","author":"Eriksson","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2005.03.003_bib39","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1111\/j.1538-7836.2003.00494.x","article-title":"The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for prophylaxis of VTE in total hip or total knee replacement: the EXPRESS study","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2005.03.003_bib40","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1046\/j.1538-7836.2003.00368.x","article-title":"Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomised, double-blind study","volume":"1","author":"Colwell","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2005.03.003_bib41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-137-8-200210150-00008","article-title":"Ximelagatran versus warfarin for the prevention of VTE after total knee arthroplasty","volume":"137","author":"Francis","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2005.03.003_bib42","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMoa035162","article-title":"Comparison of Ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement","volume":"349","author":"Francis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2005.03.003_bib43","first-page":"11","article-title":"Randomised, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) EXULT-b [abstract]","volume":"102","author":"Colwell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2005.03.003_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2003-12-4195","article-title":"New anticoagulants","volume":"105","author":"Hirsh","year":"2005","journal-title":"Blood"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620505001238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620505001238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T20:03:00Z","timestamp":1552420980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620505001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0953620505001238"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2005.03.003","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}